Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This case report describes a patient with psoriasis who developed alopecia with unique histological features after anti-TNF therapy, suggesting that such effects may require considering treatment suspension for severe cases.

This study found that anifrolumab effectively reduced disease activity and allowed for corticosteroid tapering in patients with systemic lupus erythematosus at Kanazawa University Hospital.

Dupilumab may help treat alopecia areata, but more research is needed.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

This study reported that dupilumab, a human monoclonal antibody, induced hair regrowth in patients with alopecia totalis, suggesting its potential as a treatment for this condition.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This case report describes regression of hidradenitis suppurativa lesions in two patients after 16 weeks of adalimumab treatment.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

In this study, 16% of patients on dupilumab for atopic dermatitis experienced mild cutaneous adverse events, most commonly facial redness and psoriasis, leading to discontinuation in about 3% of cases.

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Dupilumab can both improve and worsen alopecia areata, needing more research.

This study describes a case where a 2-year-old girl with severe alopecia areata showed marked hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but due to concurrent therapies and potential spontaneous recovery, improvements cannot solely be attributed to dupilumab.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.